The parties and the court

The case is Astellas Pharma Inc. v. Apotex Inc., No. 3:26-cv-14777 (D.N.J.), filed November 16, 2026. The plaintiffs are Astellas Pharma Inc., a Japanese corporation based in Tokyo, and Astellas US LLC, Astellas Pharma US, Inc., Medivation LLC, and Medivation Prostate Therapeutics LLC, each a Delaware entity. Astellas US LLC and Astellas Pharma US, Inc. are based in Northbrook, Illinois, and the Medivation plaintiffs are based in New York. The complaint alleges, on information and belief, that Apotex Inc. is a Canadian corporation based in Toronto, that Apotex Corp. is a Delaware corporation based in Weston, Florida, and that Apotex Corp. is a wholly-owned subsidiary and U.S. affiliate of Apotex Inc. Astellas Pharma US, Inc. filed NDA No. 213674 for Xtandi (enzalutamide) tablets, 40 mg and 80 mg, which the complaint says the FDA approved on August 4, 2020. The complaint's Local Rule 11.2 certification identifies two related actions, No. 3:26-cv-12995 and No. 3:26-cv-13220 (D.N.J.).

The patents

The complaint asserts U.S. Patents 11,839,689, titled Formulations of Enzalutamide, issued December 12, 2023; 12,161,628, titled Combination Therapy, issued December 10, 2024; and 12,502,357, titled Formulations of Enzalutamide, issued December 23, 2025. It says each issued to Astellas Pharma Inc. and Medivation Prostate Therapeutics LLC and is listed in the Orange Book for Xtandi 40 mg and 80 mg tablets, and that Astellas Pharma Inc. holds an exclusive license, with sublicenses to Astellas US LLC and Astellas Pharma US, Inc. As the complaint quotes them, claim 1 of the '689 patent recites "a pharmaceutical composition comprising a solid dispersion consisting essentially of amorphous enzalutamide and hydroxypropyl methylcellulose acetate succinate" (HPMCAS); claim 1 of the '628 patent recites a "method of treating prostate cancer in a patient to whom rifampin is administered, comprising co-administering to the patient a daily dose of 240 mg of enzalutamide"; and claim 1 of the '357 patent recites a "method of treating prostate cancer comprising administering to a patient in need thereof a tablet comprising a solid dispersion comprising amorphous enzalutamide and hydroxypropyl methylcellulose acetate succinate."

The notice letter and the counts

The complaint says Apotex's notice letter, dated October 2, 2026, reported that ANDA No. 221907 seeks approval to manufacture, use, or sell enzalutamide 40 mg, 80 mg, 120 mg, and 160 mg tablets before the '689 and '357 patents expire, and that the submission included a Paragraph IV certification that, in Apotex's opinion, the claims of those two patents are invalid, unenforceable, and/or not infringed. It alleges, on information and belief, that the ANDA was submitted under section 505(j) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 355(j), as generic versions of Xtandi 40 mg and 80 mg tablets. The complaint says the letter does not allege invalidity under 35 U.S.C. 101, 102, 103, or 112, or unenforceability, of any claim of the '689 and '357 patents, and it argues that Apotex thereby admits those claims are valid under 35 U.S.C. 101, 102, 103, and 112 and are enforceable. Plaintiffs say they sued within 45 days of receiving the letter.

Count I alleges infringement of the '689 patent under 35 U.S.C. 271(e)(2)(A) by the ANDA submission and alleges, on information and belief, that commercial manufacture, use, sale, offer for sale, or importation of the proposed products would directly infringe that patent under 35 U.S.C. 271(a), literally or under the doctrine of equivalents. Count II alleges infringement of the '628 patent under 35 U.S.C. 271(e)(2)(A) and, on information and belief, induced infringement of at least claim 1 of that patent under 35 U.S.C. 271(b). Count III seeks a declaratory judgment of induced infringement of the '628 patent under 35 U.S.C. 271(b). Count IV alleges infringement of the '357 patent under 35 U.S.C. 271(e)(2)(A) and alleges, on information and belief, that commercial activity with the proposed products would induce infringement of that patent under 35 U.S.C. 271(b) and would contributorily infringe it under 35 U.S.C. 271(c). The complaint also alleges, on information and belief, that Apotex copied the claimed inventions of the three patents, and that Apotex's statement of its bases for noninfringement of the '689 and '357 patents is "devoid of an objective good faith basis in either the facts or the law," and it says the case is exceptional.

Relief sought

The plaintiffs ask for judgments of infringement under 35 U.S.C. 271(e)(2)(A), a judgment or declaration that commercial activity will infringe under 35 U.S.C. 271(a), (b), and/or (c), a permanent injunction under 35 U.S.C. 271(e)(4)(B) and/or 283 against commercial activity before the patents expire, inclusive of any extensions, an order under 35 U.S.C. 271(e)(4)(A) that any FDA approval of the ANDA be effective no earlier than the patents' expiration, inclusive of any extensions, a declaration that the case is exceptional under 35 U.S.C. 285 with an award of attorney fees, and costs and expenses.

What to watch next

Watch for Apotex's answer or other response and for a scheduling order, and whether the court coordinates this case with No. 3:26-cv-12995 and No. 3:26-cv-13220. The case can end at any time, including by settlement or voluntary dismissal.